Dr. Shinichiro (Shin) Fuse, an experienced biotech investor, is a Managing Director at MPM Capital and an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM. Shin also supports MPM’s relationship with Astellas and is a Board Member of iOmx, Orna Therapeutics and Triplet Therapeutics. Shin serves as a board observer for CODA Biotherapeutics, and recently in operational roles at MPM portfolio companies as the interim CEO of Orna Therapeutics and interim SVP of Business Development at ElevateBio.

Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with Five Prime Therapeutics, National Cancer Institute and the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He also serves as a columnist for Nikkei Biotech, the leading biotech journal in Japan.

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.